The FDA on July 31, 2023, approved JEMPERLIĀ®Ā with Carboplatin and Paclitaxel, followed by single-agent JEMPERLIĀ®, for primary advanced or recurrent Endometrial Cancer (EC) that is MisMatch Repair deficient (dMMR), as determined by an FDA-approved test, or MicroSatellite Instability-High (MSI-H). JEMPERLIĀ® is a product of GlaxoSmithKline.
Other Pages – Bottom Ad
Advertisement
Subscribe
